胰腺癌循环肿瘤细胞检测技术及临床应用前景

杨笑盈; 秦骋; 赵邦博; 李天浩; 曹洪滔; 王维斌

doi:10.12290/xhyxzz.2020-0005

胰腺癌循环肿瘤细胞检测技术及临床应用前景

doi: 10.12290/xhyxzz.2020-0005

基金项目:

国家自然科学基金 81773215

详细信息

通讯作者:
王维斌电话：010-69152610，E-mail: wwb_xh@163.com

中图分类号: R735.9
计量
- 文章访问数: 127
- HTML全文浏览量: 155
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-03
- 录用日期: 2020-12-28
- 网络出版日期: 2021-11-26
- 发布日期: 2021-02-05
- 刊出日期: 2021-09-30

Detection Technology and Prospects of Clinical Application of Circulating Tumor Cells in Pancreatic Cancer

Funds:

National Natural Science Foundation of China 81773215

More Information

Corresponding author: WANG Weibin Tel: 86-10-69152610, E-mail: wwb_xh@163.com

摘要

摘要: 胰腺癌是消化系统高度恶性的肿瘤之一，其早期即可发生远处转移，患者生存期较短、预后较差。循环肿瘤细胞(circulating tumor cells, CTCs)是一类可进入血液循环的肿瘤细胞，不仅具有与原发肿瘤细胞相似的特征，且与肿瘤远处转移的关系更为密切。体外定量检测CTCs对胰腺癌的早期诊断、辅助分期、疗效及预后评估均具有重要意义。本文对胰腺癌CTCs富集方法及CTCs检测在胰腺癌筛查、远处转移与预后评估中的应用进行综述。
- 胰腺癌 /
- 循环肿瘤细胞 /
- 液体活检
Abstract: Pancreatic cancer is one of the highly malignant tumors of the digestive system, and early metastasis is an important reason for its short survival time. Circulating tumor cells (CTCs) are a type of tumor cells that are released into the bloodstream from the primary tumor and/or metastatic sites, which have properties similar to primary tumor cells and are closely related to distant metastasis of tumors. In vitro quantitative detection of CTCs is of great significance in the early diagnosis, auxiliary staging, treatment efficacy, and prognosis evaluation of pancreatic cancer. Here we generally reviewed current research on the CTCs enrichment methods of pancreatic cancer and its application in screening pancreatic cancer and metastasis, and evaluating the prognosis.
- pancreatic cancer /
- circulating tumor cells /
- liquid biopsy

HTML全文

参考文献(44)

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 7-30. doi: 10.3322/caac.21590
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66: 115-232. doi: 10.3322/caac.21338
[3]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68: 7-30. doi: 10.3322/caac.21442
[4]	Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT[J]. Radiology, 2011, 260: 446-453. doi: 10.1148/radiol.11103548
[5]	Becker AE, Hernandez YG, Frucht H, et al. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection[J]. World J Gastroenterol, 2014, 20: 11182-11198. doi: 10.3748/wjg.v20.i32.11182
[6]	Lee J, Park SS, Lee YK, et al. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA[J]. Mol Oncol, 2019, 13: 1623-1650. doi: 10.1002/1878-0261.12537
[7]	Malafa MP, Permuth J, Chen D. MicroRNA assay for detection and management of pancreatic cancer precursors[P]. U.S. Patent, 2019, 10: 240.
[8]	Yang ZJ, LaRiviere MJ, Ko J, et al. A multi-analyte panel consisting of extracellular vesicle miRNAs and mRNAs, cfDNA, and CA19-9 shows utility for diagnosis and staging of pancreatic adenocarcinoma[J]. Clin Cancer Res, 2020, 26: 3248-3258. doi: 10.1158/1078-0432.CCR-19-3313
[9]	Bernard V, Kim DU, San LFA, et al. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer[J]. Gastroenterology, 2019, 156: 108-118. doi: 10.1053/j.gastro.2018.09.022
[10]	Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Aust Med J, 1869, 14: 146.
[11]	乔雪峰, 张玉娟, 崔巍. 循环肿瘤细胞致肿瘤血行转移研究进展[J]. 协和医学杂志, 2014, 5: 331-334. doi: 10.3969/j.issn.1674-9081.2014.03.017
[12]	Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells[J]. Nat Rev Cancer, 2008, 8: 329-340. doi: 10.1038/nrc2375
[13]	Vaidyanathan R, Soon RH, Zhang P, et al. Cancer diagnosis: from tumor to liquid biopsy and beyond[J]. Lab Chip, 2018, 19: 11-34. http://www.ncbi.nlm.nih.gov/pubmed/30480287
[14]	Hao S, Wan Y, Xia Y, et al. Size-based separation methods of circulating tumor cells[J]. Adv Drug Deliv Rev, 2018, 125: 3-20. doi: 10.1016/j.addr.2018.01.002
[15]	Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells[J]. Am J Pathol, 2000, 156: 57-63. doi: 10.1016/S0002-9440(10)64706-2
[16]	Burinaru TA, Avram M, Avram A, et al. Detection of Circulating Tumor Cells Using Microfluidics[J]. ACS Comb Sci, 2018, 20: 107-126. doi: 10.1021/acscombsci.7b00146
[17]	Riethdorf S, O'Flaherty L, Hille C, et al. Clinical applications of the CellSearch platform in cancer patients[J]. Adv Drug Deliv Rev, 2018, 125: 102-121. doi: 10.1016/j.addr.2018.01.011
[18]	Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas[J]. Hum Pathol, 2004, 35: 122-128. doi: 10.1016/j.humpath.2003.08.026
[19]	Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker[J]. Br J Cancer, 2012, 106: 508-516. doi: 10.1038/bjc.2011.545
[20]	杨卓, 张玉娟, 陈倩, 等. 循环肿瘤细胞检测及其特性[J]. 协和医学杂志, 2013, 4: 191-194. doi: 10.3969/j.issn.1674-9081.2013.02.023
[21]	Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology[J]. Nature, 2007, 450: 1235-1239. doi: 10.1038/nature06385
[22]	Iwanicki-Caron I, Basile P, Toure E, et al. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis[J]. Am J Gastroenterol, 2013, 108: 152-155. doi: 10.1038/ajg.2012.367
[23]	Zhang W, Bao L, Yang S, et al. Tumor-selective replication herpes simplex virus-based technology signifi-cantly improves clinical detection and prognostication of viable circulating tumor cells[J]. Oncotarget, 2016, 7: 39768-39783. doi: 10.18632/oncotarget.9465
[24]	Chang C, Huang W, Jalal SI, et al. Circulating tumor cell detection using a parallel flow micro-aperture chip system[J]. Lab Chip, 2015, 15: 1677-1688. doi: 10.1039/C5LC00100E
[25]	Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148: 349-361. doi: 10.1016/j.cell.2011.11.025
[26]	Rhim AD, Thege FI, Santana SM, et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions[J]. Gastroenterology, 2014, 146: 647-651. doi: 10.1053/j.gastro.2013.12.007
[27]	Cauley CE, Pitman MB, Zhou J, et al. Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings[J]. J Am Coll Surg, 2015, 221: 699-707. doi: 10.1016/j.jamcollsurg.2015.05.014
[28]	Kamande JW, Hupert ML, Witek MA, et al. Modular microsystem for the isolation, enumeration, and phenotyping of circulating tumor cells in patients with pancreatic cancer[J]. Anal Chem, 2013, 85: 9092-9100. doi: 10.1021/ac401720k
[29]	Court CM, Ankeny JS, Sho S, et al. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer[J]. Ann Surg Oncol, 2018, 25: 1000-1008.
[30]	Kulemann B, Pitman MB, Liss AS, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer[J]. Pancreas, 2015, 44: 547-550. doi: 10.1097/MPA.0000000000000324
[31]	Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen[J]. Cancer Control, 2008, 15: 280-287. doi: 10.1177/107327480801500402
[32]	Soeth E, Grigoleit U, Moellmann B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival[J]. J Cancer Res Clin Oncol, 2005, 131: 669-676. doi: 10.1007/s00432-005-0008-1
[33]	Kurihara T, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result[J]. J Hepatobiliary Pancreat Surg, 2008, 15: 189-195. doi: 10.1007/s00534-007-1250-5
[34]	de Albuquerque A, Kubisch I, Breier G, et al. Multi-marker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study[J]. Oncology, 2012, 82: 3-10. doi: 10.1159/000335479
[35]	Bidard FC, Huguet F, Louvet C, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial[J]. Ann Oncol, 2013, 24: 2057-2061. doi: 10.1093/annonc/mdt176
[36]	Gao Y, Zhu Y, Zhang Z, et al. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization[J]. J Exp Clin Cancer Res, 2016, 35: 66. doi: 10.1186/s13046-016-0340-0
[37]	Poruk KE, Valero V, Saunders T, et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma[J]. Ann Surg, 2016, 264: 1073-1081. doi: 10.1097/SLA.0000000000001600
[38]	Stephenson D, Nahm C, Chua T, et al. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8: 107223-107236. doi: 10.18632/oncotarget.19928
[39]	Effenberger KE, Schroeder C, Hanssen A, et al. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer[J]. Clin Cancer Res, 2018, 24: 2844-2850. doi: 10.1158/1078-0432.CCR-18-0120
[40]	Chang M, Chang Y, Chen J, et al. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma[J]. Clin Chem, 2016, 62: 505-513. doi: 10.1373/clinchem.2015.248260
[41]	Catenacci DV, Chapman CG, Xu P, et al. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound[J]. Gastroenterology, 2015, 149: 1794-1803. doi: 10.1053/j.gastro.2015.08.050
[42]	Bissolati M, Sandri MT, Burtulo G, et al. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer[J]. Tumour Biol, 2015, 36: 991-996. doi: 10.1007/s13277-014-2716-0
[43]	Tien YW, Kuo H, Ho B, et al. A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases[J]. Medicine (Baltimore), 2016, 95: e3407. doi: 10.1097/MD.0000000000003407
[44]	Nagrath S, Jack RM, Sahai V, et al. Opportunities and Challenges for Pancreatic Circulating Tumor Cells[J]. Gastroenterology, 2016, 151: 412-426. doi: 10.1053/j.gastro.2016.05.052